talkbio – Page 11

Inside ASCO 2025: Big Data Drops and a Towering Campaign – Key News Highlights

4 weeks ago talkbio0Tagged 2025, Artificial Intelligence, ASCO, Big Data, campaigns, Cancer Research, Clinical Oncology, erbB-2 Receptor, Malignant neoplasm of breast, Malignant neoplasm of lung

ASCO 2025; cancer research; big data; campaigns; clinical oncology; artificial intelligence; HER2; lung cancer; breast cancer; therapeutic vaccines

Vertex Lays Off 125 Staffers, Shrinks Rhode Island Campus After Diabetes Therapy Setback

4 weeks ago talkbio0Tagged cell-device combo, Clinical trial failure, Diabetes Therapy, facility consolidation, layoffs, Rhode Island, VX-264

Vertex Pharmaceuticals; layoffs; Rhode Island; diabetes therapy; VX-264; cell-device combo; clinical trial failure; facility consolidation

New Rules and Regulatory Trends in Biopharma Manufacturing in 2025

4 weeks ago talkbio0Tagged Biopharma, country-of-origin labeling, digital quality systems, forced labor compliance, green manufacturing, import rules, Manufacturing, regulatory, Serialization, Trump administration tariffs, United States Food and Drug Administration

biopharma manufacturing; 2025 regulations; FDA; digital quality systems; green manufacturing; import rules; Trump administration tariffs; country-of-origin labeling; forced labor compliance; serialization

Insmed’s TPIP PAH Therapy Advances to Phase III Following Positive Phase 2b Results

4 weeks ago talkbio0Tagged Clinical Trials, Engaged to be married, Insmed, PAH, Phase 3 Clinical Trials, Pulmonary arterial hypertension, TPTE2 gene, treprostinil palmitil inhalation powder, United States Food and Drug Administration

Insmed; TPIP; treprostinil palmitil inhalation powder; pulmonary arterial hypertension; PAH; Phase 2b trial; Phase III trial; clinical trial results; FDA engagement

FDA Places Clinical Hold on Five Gilead HIV Studies Due to Safety Concerns

4 weeks ago talkbio0Tagged Biktarvy, CD4 + T-cell, Clinical Trials, Gilead Sciences, GS-1720, GS-4182, HIV, Lenacapavir, Lymphocyte Count measurement, safety signal, Study on Hold, United States Food and Drug Administration

FDA; Gilead Sciences; HIV; clinical hold; GS-1720; GS-4182; clinical trials; safety signal; CD4+ T-cell; lymphocyte count; Biktarvy; lenacapavir

Antares Therapeutics Launches with $177M to Tackle ‘Undruggable’ Targets After Scorpion Spinout

4 weeks ago talkbio0Tagged Antares, biotech spinoff, Eli Lilly acquisition, Neoplasms, Precision Medicine, preclinical pipeline, Scorpions, targets

Antares Therapeutics; Scorpion Therapeutics; biotech spinoff; $177M Series A; undruggable targets; oncology; precision medicine; Eli Lilly acquisition; preclinical pipeline